Innate Immunotherapeutics (ATX AU): 2022 Is Going to Be a Watershed Year

Smartkarma
2022-04-12

The company is scheduled to start two phase 2 trials for its lead asset, with first results expected in mid-2023. Investors, with high-risk appetite can go for this stock ahead of key milestones.

  • Innate Immunotherapeutics (ATX AU) is an Australian pharmaceutical company advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis.
  • The company’s primary focus for 2022 is on initiating phase 2 clinical trials in pancreatic cancer and, in the second half of the year in lung fibrosis.
  • With latest quarter’s cash burn of AUD0.94 million and cash balance of AUD16.2 million, the company is well-positioned to fund its near-term R&D activities.

By Tina Banerjee - https://www.smartkarma.com/profiles/tina-banerjee?utm_source=tiger_community

On Innate Immunotherapeutics (ATX AU) - https://www.smartkarma.com/entities/amplia-therapeutics-ltd?utm_source=tiger_community

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • xnegate
    2022-04-17
    xnegate
    let's goooo
  • D.Billions
    2022-04-14
    D.Billions
    good to see thus
  • Dragonroar
    2022-04-19
    Dragonroar
    wow oh that's something
  • mantaru
    2022-04-19
    mantaru
    biopharm *shivers
  • coldkohmew
    2022-04-19
    coldkohmew
    Fingers cro ssed
  • GerryLoh
    2022-04-18
    GerryLoh
    good sharing thanks
Leave a comment
2